Medtronic Marks 49 Straight Years of Dividend Growth While MiniMed Spinoff Takes Shape

Medtronic runs a 49-year dividend streak alongside a MiniMed exchange offer at a 7% discount, with a corrected 8-K setting the delivery deadline.

Medtronic has set two very different clocks running at the same time. One is measured in decades — the company's streak of annual dividend increases now stretches to 49 consecutive years. The other is measured in trading days, as shareholders weigh a spinoff offer that would carve the diabetes business out of the group.

The quarterly payout of $0.72 per common share for the second quarter of fiscal 2027, announced in June, reached its record date last Friday. Payment to eligible holders is scheduled for October 16, 2026. Income-focused investors have come to rely on that consistency, and the latest distribution extends a run that few industrial or medical-technology peers can match.

A Share-Swap Offer With a 7% Discount

Running alongside the dividend program is a far more complex transaction. On September 14, Medtronic launched an exchange offer aimed at separating at least 80.1% of the MiniMed Group from the parent company. Up to 225,361,295 newly issued MiniMed shares are being made available to Medtronic stockholders, and if the offer is oversubscribed, an additional 27,452,053 shares could be added.

Stockholders participating in the swap receive MiniMed equity at a 7% discount to the value of the Medtronic shares they tender. The mechanics give investors a genuine choice: remain a holder of the combined enterprise, or take a direct stake in a standalone diabetes company. Either way, the exchange reduces the number of Medtronic shares outstanding and moves the parent closer to a leaner structure, with capital redirected toward higher-margin growth areas.

Corrected Filing Tightens the Deadline

Three days after opening the offer, Medtronic filed a corrected Form 8-K on September 17 to fix a typographical error in the offering prospectus. The same filing locked in the guaranteed delivery deadline: 5:00 p.m. New York time on the second NYSE trading day following execution of the notice. Additional Rule 425 communications were also submitted, directing stockholders to an information page covering the terms of the exchange. Such disclosures are routine obligations, but they matter here — they ensure every holder understands the technical steps and timing of the separation.

Guidance Raised, Devices Cleared

The spinoff is not happening in a vacuum. Roughly three weeks ago, Medtronic lifted its fiscal 2027 outlook, calling for organic revenue growth of 7.25% to 7.75% and raising the floor of its adjusted earnings-per-share range to $5.94. The revision followed a demand recovery across several segments. Since that announcement, the stock has slipped 2.6%.

Regulatory progress has reinforced the story outside diabetes. More than a month ago, the FDA cleared the LigaSure RAS Maryland device for use with the Hugo robotic-assisted surgery system. On August 6, Medtronic extended CE marking for its Affera Mapping and Ablation System and the Sphere-9 catheter for treating ventricular arrhythmias. Each clearance adds weight to the argument that the remaining core business can carry the company after MiniMed departs.

A Quiet Friday Close

Trading gave little away. Medtronic finished Friday at EUR 77.44, a modest decline of 0.4% on the day. At that level, the company's market capitalization stands at roughly EUR 99.29 billion — or EUR 100.42 billion depending on the conversion basis used. For all the strategic activity, the market's response has been restrained, and attention now turns to how the trimmed-down group performs once the MiniMed separation is complete.